You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
睿昂基因(688217.SH):一直非常重視充分利用政府的補貼政策
格隆匯 04-19 16:16

格隆匯4月19日丨有投資者向睿昂基因(688217.SH)提問:國家對於腫瘤行業是否有哪些政策扶持?今明年還有哪些補貼嗎?

睿昂基因回覆:您好。我國政府頒佈了諸多產業政策,支持體外診斷行業的發展,具體政策如下所示:《國務院關於實施健康中國行動的意見》(國發〔2019〕13號)、《國務院辦公廳關於印發深化醫藥衞生體制改革2019年重點工作任務的通知》(國辦發〔2019〕28號)、《國務院辦公廳關於印發深化醫藥衞生體制改革2018年下半年重點工作任務的通知》(國辦發〔2018〕83號)、《關於鞏固破除以藥補醫成果持續深化公立醫院綜合改革的通知》(國衞體改發[2018]4號)、《“十三五”衞生與健康科技創新專項規劃》、《“十三五”醫療器械科技創新專項規劃》、《“十三五”生物產業發展規劃》(發改高技[2016]2665號)、《“十三五”國家戰略性新興產業發展規劃》(國發[2016]67號)等。

對於補貼,公司一直非常重視充分利用政府的補貼政策,並有專門的政府事務部負責跟進對接。公司會根據業務實際發生情況,如技改投資、税收繳納等相關政府補貼政策去申請如張江項目、技改貼息等補貼。感謝您的關注。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account